JP2024516595A - 修飾された抗ｔｓｌｐ抗体 - Google Patents

修飾された抗ｔｓｌｐ抗体 Download PDF

Info

Publication number
JP2024516595A
JP2024516595A JP2023563978A JP2023563978A JP2024516595A JP 2024516595 A JP2024516595 A JP 2024516595A JP 2023563978 A JP2023563978 A JP 2023563978A JP 2023563978 A JP2023563978 A JP 2023563978A JP 2024516595 A JP2024516595 A JP 2024516595A
Authority
JP
Japan
Prior art keywords
seq
antibody
fragment
tslp
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516595A5 (https=
JPWO2022226342A5 (https=
Inventor
ボンダレンコ，パベル
シー，リウチン
ジャン，ハオ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2024516595A publication Critical patent/JP2024516595A/ja
Publication of JP2024516595A5 publication Critical patent/JP2024516595A5/ja
Publication of JPWO2022226342A5 publication Critical patent/JPWO2022226342A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023563978A 2021-04-23 2022-04-22 修飾された抗ｔｓｌｐ抗体 Pending JP2024516595A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178915P 2021-04-23 2021-04-23
US63/178,915 2021-04-23
PCT/US2022/025999 WO2022226342A2 (en) 2021-04-23 2022-04-22 Modified anti-tslp antibodies

Publications (3)

Publication Number Publication Date
JP2024516595A true JP2024516595A (ja) 2024-04-16
JP2024516595A5 JP2024516595A5 (https=) 2025-05-01
JPWO2022226342A5 JPWO2022226342A5 (https=) 2025-05-01

Family

ID=81597885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563978A Pending JP2024516595A (ja) 2021-04-23 2022-04-22 修飾された抗ｔｓｌｐ抗体

Country Status (14)

Country Link
US (1) US20240182558A1 (https=)
EP (1) EP4326762A2 (https=)
JP (1) JP2024516595A (https=)
KR (1) KR20230175245A (https=)
CN (1) CN117177992A (https=)
AR (1) AR125404A1 (https=)
AU (1) AU2022262006A1 (https=)
BR (1) BR112023022041A2 (https=)
CA (1) CA3216700A1 (https=)
CL (1) CL2023003124A1 (https=)
IL (1) IL307439A (https=)
MX (1) MX2023012325A (https=)
TW (1) TW202304980A (https=)
WO (1) WO2022226342A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024118542A1 (en) * 2022-11-28 2024-06-06 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions
CN120513100A (zh) * 2023-01-06 2025-08-19 江苏恒瑞医药股份有限公司 一种tslp抗体治疗哮喘的方法
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
CN121443636A (zh) 2023-05-18 2026-01-30 免疫医疗有限责任公司 用抗tslp抗体治疗皮质类固醇依赖性哮喘
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025265071A1 (en) * 2024-06-21 2025-12-26 Paragon Therapeutics, Inc. Antibodies that bind tslp and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538608A (ja) * 2007-09-10 2010-12-16 アムジェン インコーポレイテッド 胸腺間質性リンパ球性新生因子に結合することができる抗原結合タンパク質
WO2021043221A1 (en) * 2019-09-04 2021-03-11 Biosion Inc. Antibodies binding tslp and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
JP4986633B2 (ja) * 2005-01-12 2012-07-25 協和発酵キリン株式会社 安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
BR112017019412A2 (pt) * 2015-03-11 2018-05-02 Glaxosmithkline Ip Dev Ltd proteínas ligadoras de tslp
KR20240070727A (ko) 2017-04-12 2024-05-21 암젠 인크 항-tslp 항체를 이용한 천식의 치료
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
SG11202000727SA (en) * 2017-08-01 2020-02-27 Amgen Inc Systems and methods for real time preparation of a polypeptide sample for analysis with mass spectrometry
CA3079665A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
ES3042632T3 (en) 2018-03-13 2025-11-24 Amgen Inc Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
EA202191038A1 (ru) 2018-10-15 2021-07-06 Эмджен Инк. Способ платформенной сборки для устройства доставки лекарственного средства
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
MA56121A (fr) 2019-06-05 2022-04-13 Amgen Inc Procédés d'identification d'attributs de protéines thérapeutiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538608A (ja) * 2007-09-10 2010-12-16 アムジェン インコーポレイテッド 胸腺間質性リンパ球性新生因子に結合することができる抗原結合タンパク質
WO2021043221A1 (en) * 2019-09-04 2021-03-11 Biosion Inc. Antibodies binding tslp and uses thereof

Also Published As

Publication number Publication date
TW202304980A (zh) 2023-02-01
AR125404A1 (es) 2023-07-12
AU2022262006A1 (en) 2023-10-19
MX2023012325A (es) 2023-10-30
KR20230175245A (ko) 2023-12-29
WO2022226342A3 (en) 2022-12-01
EP4326762A2 (en) 2024-02-28
WO2022226342A2 (en) 2022-10-27
CL2023003124A1 (es) 2024-04-26
IL307439A (en) 2023-12-01
US20240182558A1 (en) 2024-06-06
CN117177992A (zh) 2023-12-05
BR112023022041A2 (pt) 2023-12-26
CA3216700A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
US20240182558A1 (en) Modified anti-tslp antibodies
US20250032608A1 (en) Treatment of asthma with anti-tsl p antibody
CN109863173B (zh) 抗-il-33抗体及其用途
EP4289861A1 (en) Antibodies against human tslp and use thereof
JP2022023049A (ja) バイオ医薬組成物
US20240190951A1 (en) Anti-tslp antibody compositions and uses thereof
AU2021221998A1 (en) Formulations of human anti-TSLP antibodies and methods of using the same
KR20260007589A (ko) 인터류킨 13에 결합하는 항체를 투여하는 방법
IL302445A (en) Use of an IL-18 antagonist for the treatment and/or prevention of atopic dermatitis or a related condition
WO2025221933A1 (en) Antibodies and polypeptides comprising variant fc regions
WO2024092064A1 (en) Anti-tslp antibody compositions and uses thereof
WO2025049347A1 (en) Klk5/7 + il-4 targeting antibodies and uses thereof
AU2024331904A1 (en) Klk5/7 + il-13 targeting antibodies and uses thereof
WO2025166146A1 (en) Klk5/7 + ox40 targeting antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224